MedTrace Logo

South Of France Cardiac Assist Registry

NCT02877446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-08-11

No results posted yet for this study

Summary

Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure.

Heart transplantation represents the "gold standard" of care for terminal heart failure patients reached the end of the disease despite optimal medical and surgical management of their disease, with a survival rate of transplant patients by 90% at 1 year and 82% at 3 years.

Long term LVAD are an innovative technology available for more than a decade, developed in part because of the shortage of cardiac grafts and high mortality among patients waiting for transplants due to an important pending.

This technique is used substantially only for ten to fifteen years in the world. Survival after implantation of latest devices reaches 80% at 1 year.

In France, this technique is intended for patients with terminal heart failure who ended different pharmacological and invasive therapeutic resources available.

Currently, academic centers that offer the possibility of long-term LVAD support are organized unicentric in order to centralize specialized care for these patients.

Indeed, patients candidates for the establishment of a long-term LVAD are rigorously selected to ensure an acceptable survival.

However, practices vary considerably from one center to another in particular regarding:

* Implantation indications,
* Pre-implantation patient assessment,
* Monitoring,
* Implementation of pharmacological treatments, particularly anticoagulants or betablockers.

Conditions

  • Chronic or Acute Advanced Heart Failure

Sponsors & Collaborators

  • University Hospital, Toulouse

    collaborator OTHER

  • University Hospital, Bordeaux

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Francois Roubille, MD PHD · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2022-04-30
Completion
2022-08-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877446 on ClinicalTrials.gov